Purchase Order 75N91018P00539

<p>The National Cancer Institute awarded a purchase order to Adaptive Biotechnologies Corporation for $11,930.00 on August 2, 2018, with an ultimate completion date of September 28, 2018. Work is performed in Seattle, Washington. The order procures immunosequencing services and diagnostic testing delivered under firm fixed-price pricing.</p>

<p>The National Cancer Institute awarded a purchase order to Adaptive Biotechnologies Corporation valued at $14,337.50 on February 28, 2019, for immunosequencing services. Performance is located in Seattle, Washington. The order carries a firm fixed-price structure with an ultimate completion date of May 31, 2019. No set-aside applies to this procurement.</p>

<p>The National Cancer Institute awarded a purchase order to Adaptive Biotechnologies Corporation valued at $19,350 on September 6, 2018, with completion by November 12, 2018. Place of performance is Seattle, Washington. The order is firm fixed price with no set-aside designation. Adaptive Biotechnologies, a Seattle-based biotechnology company, supplies immunosequencing services and minimal residual disease diagnostic testing to federal health research and defense medical agencies.</p>

<p>The National Cancer Institute awarded a purchase order to Adaptive Biotechnologies Corporation for $6,750.00 on August 29, 2017, with completion scheduled for September 30, 2017. Performance is located in San Diego, California. The order covers DNA services using Adaptive's immunosequencing capabilities. This is a firm fixed-price acquisition with no set-aside designation.</p>

<p>The National Cancer Institute issued a purchase order to Adaptive Biotechnologies Corporation on April 29, 2019, for lab testing services valued at $15,062.50, with ultimate completion on May 29, 2019. Performance takes place in Seattle, Washington. The order procures laboratory testing services on a firm fixed-price basis without set-aside designation.</p>

<p>The National Cancer Institute awarded a purchase order to Adaptive Biotechnologies Corporation for $4,662.50 on July 20, 2017, for DNA extraction services. Place of performance is Seattle, Washington. The order carries a firm fixed-price structure with an ultimate completion date of August 18, 2017.</p>

<p>The National Cancer Institute awarded a purchase order to Adaptive Biotechnologies Corporation for DNA extraction services valued at $12,475.00, with an award date of April 3, 2019 and ultimate completion on May 3, 2019. Work is performed in Seattle, Washington. No set-aside applies. The order is priced on a firm fixed-price basis for commercial laboratory services.</p>

<p>The National Cancer Institute awarded a purchase order to Adaptive Biotechnologies Corporation for $20,850 on September 11, 2020, with final completion on December 11, 2020. The order covers laboratory testing services on a firm fixed-price basis with no set-aside designation. Work is performed in Bethesda, Maryland.</p>

<p>The National Cancer Institute awarded a purchase order to Adaptive Biotechnologies Corporation for $13,350.00 on December 27, 2018, for DNA extraction service, domestic shipping, and TCRB V4 service deep and survey work. Work is performed in Seattle, Washington. The order carries a firm fixed-price structure with an ultimate completion date of February 28, 2019.</p>

<p>The National Cancer Institute awarded a purchase order to Adaptive Biotechnologies Corporation for $4,587.50 on August 24, 2017, for DNA services. Performance is located in San Diego, California, with an ultimate completion date of September 30, 2017. The order carries firm fixed price terms.</p>